JP2020527556A - がん治療用ペプチドサポリン複合体 - Google Patents

がん治療用ペプチドサポリン複合体 Download PDF

Info

Publication number
JP2020527556A
JP2020527556A JP2020501231A JP2020501231A JP2020527556A JP 2020527556 A JP2020527556 A JP 2020527556A JP 2020501231 A JP2020501231 A JP 2020501231A JP 2020501231 A JP2020501231 A JP 2020501231A JP 2020527556 A JP2020527556 A JP 2020527556A
Authority
JP
Japan
Prior art keywords
mgs
peptides
composition according
peptide
saporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020501231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527556A5 (https=
Inventor
キャスリン シー ブラウン
キャスリン シー ブラウン
カーティス オールレッド
カーティス オールレッド
マイケル マグワイア
マイケル マグワイア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc filed Critical SRI International Inc
Publication of JP2020527556A publication Critical patent/JP2020527556A/ja
Publication of JP2020527556A5 publication Critical patent/JP2020527556A5/ja
Priority to JP2023189168A priority Critical patent/JP2024012517A/ja
Priority to JP2025283311A priority patent/JP2026062852A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020501231A 2017-07-10 2018-07-10 がん治療用ペプチドサポリン複合体 Pending JP2020527556A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023189168A JP2024012517A (ja) 2017-07-10 2023-11-06 がん治療用ペプチドサポリン複合体
JP2025283311A JP2026062852A (ja) 2017-07-10 2025-12-26 がん治療用ペプチドサポリン複合体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530674P 2017-07-10 2017-07-10
US62/530,674 2017-07-10
PCT/US2018/041412 WO2019014199A1 (en) 2017-07-10 2018-07-10 PEPTIDE SAPORIN CONJUGATE FOR THE TREATMENT OF CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023189168A Division JP2024012517A (ja) 2017-07-10 2023-11-06 がん治療用ペプチドサポリン複合体

Publications (2)

Publication Number Publication Date
JP2020527556A true JP2020527556A (ja) 2020-09-10
JP2020527556A5 JP2020527556A5 (https=) 2021-08-26

Family

ID=65002607

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020501231A Pending JP2020527556A (ja) 2017-07-10 2018-07-10 がん治療用ペプチドサポリン複合体
JP2023189168A Pending JP2024012517A (ja) 2017-07-10 2023-11-06 がん治療用ペプチドサポリン複合体
JP2025283311A Pending JP2026062852A (ja) 2017-07-10 2025-12-26 がん治療用ペプチドサポリン複合体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023189168A Pending JP2024012517A (ja) 2017-07-10 2023-11-06 がん治療用ペプチドサポリン複合体
JP2025283311A Pending JP2026062852A (ja) 2017-07-10 2025-12-26 がん治療用ペプチドサポリン複合体

Country Status (6)

Country Link
US (2) US11738089B2 (https=)
EP (1) EP3652195A4 (https=)
JP (3) JP2020527556A (https=)
CN (2) CN118240025A (https=)
AU (2) AU2018301651B2 (https=)
WO (1) WO2019014199A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023503797A (ja) * 2019-10-01 2023-02-01 キャスリン シー ブラウン 分子ガイドシステムペプチド及びその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11965004B2 (en) 2017-07-10 2024-04-23 Sri International Molecular guide system peptides and uses thereof
CN118240025A (zh) 2017-07-10 2024-06-25 斯坦福国际研究院 用于治疗癌症的肽皂草素缀合物
US12516086B2 (en) 2021-12-21 2026-01-06 Sri International Dual targeting for cell-specific delivery to the central nervous system
US20250215411A1 (en) * 2022-03-09 2025-07-03 Ospedale San Raffaele Srl Fusion proteins and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508515A (ja) * 2011-01-13 2014-04-10 ウニベルシタット アウトノマ デ バルセロナ Ｃｘｃｒ４細胞に治療分子を効率的かつ選択的に送達するための方法および試薬

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2004003170A2 (en) 2002-06-28 2004-01-08 The Johns Hopkins University Agents capable of inhibiting ras and uses thereof
JP2006521088A (ja) 2002-11-15 2006-09-21 メディカル リサーチ カウンシル 抗活性化ｒａｓ抗体
CA2524124C (en) 2003-04-30 2014-03-25 Uwe Zangemeister-Wittke Methods for treating cancer using an immunotoxin
WO2005081898A2 (en) 2004-02-20 2005-09-09 The Trustees Of The University Of Pennsylvania Binding peptidomimetics and uses of the same
EP1867661A1 (en) 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
US20090110662A1 (en) 2007-04-30 2009-04-30 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
WO2009089186A2 (en) * 2008-01-05 2009-07-16 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
EP2352522A4 (en) 2008-11-06 2014-03-05 Univ Washington BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8481678B2 (en) 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
CN101724073A (zh) 2010-01-19 2010-06-09 成都军区昆明总医院 一种广谱抗ras基因表达蛋白的单克隆抗体及其制备方法
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8362207B2 (en) 2010-04-16 2013-01-29 Wake Forest University Health Sciences Multi-level specific targeting of cancer cells with IL-13
WO2012040513A1 (en) * 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions and methods for the delivery of beta lapachone
CA2816584A1 (en) 2010-11-01 2012-05-10 Peptimed, Inc. Compositions of a peptide-based system for cell-specific targeting
US8515001B2 (en) 2010-12-24 2013-08-20 Lg Display Co., Ltd. Shift register
US20120283410A1 (en) 2011-03-14 2012-11-08 Intezyne Technologies, Incorporated Attachment of biological targeting groups using metal free click chemistry
US9062312B2 (en) 2011-06-21 2015-06-23 Danisco Us Inc. Fusion peptides comprising multi-functional peptidic solubility tags for efficient production, processing and surface applications
US9572898B2 (en) 2013-09-09 2017-02-21 Seton Hall University Functionalized fluorine containing phthalocyanine molecules
GB201318954D0 (en) 2013-10-28 2013-12-11 Cupid Peptide Company Ltd Cell transport
PT3137605T (pt) 2014-05-01 2020-12-18 Ionis Pharmaceuticals Inc Composições e métodos para modulação da expressão de angiopoietina de tipo 3
WO2016022597A1 (en) 2014-08-04 2016-02-11 Case Western Reserve University Targeting peptides and methods of use
EP3226840B1 (en) 2014-12-17 2020-07-29 SRI International Antigen delivery system
AU2017236431A1 (en) * 2016-03-24 2018-09-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US20180129937A1 (en) 2016-11-04 2018-05-10 Salesforce.Com, Inc. Quasi-recurrent neural network
US20180157388A1 (en) 2016-12-02 2018-06-07 Google Inc. Emotion expression in virtual environment
CA3047491A1 (en) * 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN118240025A (zh) 2017-07-10 2024-06-25 斯坦福国际研究院 用于治疗癌症的肽皂草素缀合物
US11965004B2 (en) * 2017-07-10 2024-04-23 Sri International Molecular guide system peptides and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508515A (ja) * 2011-01-13 2014-04-10 ウニベルシタット アウトノマ デ バルセロナ Ｃｘｃｒ４細胞に治療分子を効率的かつ選択的に送達するための方法および試薬

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. AM. CHEM. SOC., vol. 126, JPN6022032735, 2004, pages 15656 - 15657, ISSN: 0004975847 *
J. CELL. BIOCHEM., vol. 116, JPN6022032733, 2015, pages 1256 - 1266, ISSN: 0004975848 *
SCIENTIFIC REPORTS, vol. Vol.4, No.1, Article number:4480, JPN6022032734, 2014, pages 1 - 11, ISSN: 0004975849 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023503797A (ja) * 2019-10-01 2023-02-01 キャスリン シー ブラウン 分子ガイドシステムペプチド及びその使用

Also Published As

Publication number Publication date
US11738089B2 (en) 2023-08-29
JP2024012517A (ja) 2024-01-30
AU2023216858A1 (en) 2023-11-09
US20220226487A1 (en) 2022-07-21
AU2018301651B2 (en) 2023-05-18
EP3652195A1 (en) 2020-05-20
US12576157B2 (en) 2026-03-17
CN111417646B (zh) 2024-04-19
EP3652195A4 (en) 2021-08-04
WO2019014199A1 (en) 2019-01-17
US20240024495A1 (en) 2024-01-25
CN111417646A (zh) 2020-07-14
JP2026062852A (ja) 2026-04-10
CN118240025A (zh) 2024-06-25
AU2018301651A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
JP7742390B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP2026062852A (ja) がん治療用ペプチドサポリン複合体
JP6510410B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP2022062012A (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP7642700B2 (ja) 分子誘導システムペプチド及びその使用
US20150158914A1 (en) Peptides, constructs and uses therefor
CN103080309A (zh) REIC/Dkk-3蛋白的部分区域多肽
JP2025166082A (ja) 分子ガイドシステムペプチド及びその使用
Cesaro et al. Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia
WO2024027764A9 (en) Chimeric antigen receptor systems, methods of preparation, and uses thereof
CN112236162A (zh) 用于裂解选择性癌细胞的组合物
Ivanova et al. Impact and intracellular localization of antibodies to DNA in MDCK cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230130

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230426

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230704